# Is Ipamorelin FDA-Approved? Regulatory Status

> Is ipamorelin FDA approved? No — it has never been approved as a drug anywhere, its one Phase 2 trial failed, and in 2024 the FDA restricted its compounding-pharmacy access. The regulatory record, appraised.

Never approved as a drug, a single failed trial, a 2024 restriction on compounding access, and prohibition in sport — the status the marketing tends to skip.

## The short answer

Is ipamorelin fda approved? No. Ipamorelin has never been approved as a drug by the FDA — or by any other regulatory authority, anywhere — for any use. That is the simple, load-bearing fact, and it is worth sitting with because so much marketing implies otherwise. It was studied as a potential medicine, most seriously for sluggish bowel function after surgery, but that one human trial failed and development stopped [3]. Today it is sold only as a research chemical. On top of that, in 2024 the FDA acted to *tighten* access through compounding pharmacies, and ipamorelin is banned in competitive sport at all times. "Not approved" here does not mean "approval is still pending" — it means a drug program was tried, did not succeed, and was not pursued further.

## Never approved — and why that phrasing matters

There is an important distinction between a compound that is *new and still in trials* and one that *was tried and not approved*. Ipamorelin is the second kind. It was developed in the 1990s, characterized in 1998 as the first selective growth hormone secretagogue [1], had its human pharmacokinetics mapped in 1999 [2], and was advanced into clinical development for postoperative ileus — the only indication to reach Phase 2 [3]. There are no completed Phase 3 trials and no approved indication anywhere [3]. So when sources note ipamorelin is "not FDA-approved," the fuller truth is that its lack of approval reflects a clinical program that did not demonstrate efficacy — not merely incomplete paperwork.

## The trial that decides it

The regulatory status rests on one trial, so the appraisal has to weigh it directly. In 114 adults recovering from bowel resection, intravenous ipamorelin (0.03 mg/kg twice daily for up to seven days) missed its primary endpoint: median time to first tolerated meal was 25.3 hours versus 32.6 hours on placebo, a difference that was not statistically significant (p=0.15) [3]. Treatment-emergent adverse events were similar between groups, so the trial did not raise a specific safety flag — but it did not show the drug worked, and that is what an approval would have required [3]. No subsequent clinical program followed. This single negative result is, functionally, the reason there is no approved ipamorelin product to discuss.

## 2024: compounding access tightened

The most recent regulatory development cuts against the assumption that access is loosening. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list — the framework that governs which substances compounding pharmacies may use — following the nominator's withdrawal in September 2024. Ipamorelin acetate and free base were then reviewed at the FDA's Pharmacy Compounding Advisory Committee meeting on October 29, 2024. The practical effect is that ipamorelin is **not** an approved bulk substance for compounding, narrowing a route through which it had reached patients. The direction of travel is more restriction, not less.

## Banned in sport, and detectable

Regulatory status is not only about the FDA. Ipamorelin and other growth hormone secretagogues are prohibited in sport at all times under the World Anti-Doping Agency's category S2 (peptide hormones, growth factors, and mimetics) [7]. This is not a theoretical prohibition: accredited laboratories detect it in urine using established, published methods, including a direct-urine-injection technique that screens it alongside 17 other prohibited small peptides at picogram-per-milliliter sensitivity [9]. Analysts have even identified glycine-modified designer analogues of ipamorelin in seized doping material [7]. The detection science is covered in full on the [how long does ipamorelin stay in your system](/half-life) page. For anyone subject to testing, "not FDA-approved" and "banned and detectable in sport" are two distinct, equally important facts.

---

An evidence-appraisal reading of the Ipamorelin record — the founding selectivity data weighed against the failed Phase 2 trial and the marketing, with the anti-doping detection science laid out plainly; no clinic behind the appraisal and nothing here dosed, dispensed, or sold.